AUTHORS
Yejin Andrea Kim, MD, Prem Geeta Torlapati2, Deedra Nicolet, MS3, Krzysztof Mrózek, MD, PhD4, Michael Walker5, Justice Ameyi, M.S.6, Alice Scott Mims, MD7, Lukas Ronner, MD MSCR8, Niti Patel9, Michael Jamie Hochman, MD10, Alexander Joseph Ambinder, MD, MPH11, Brittany Knick Ragon, MD12, Stephanie Begley, MS13, Charles Foucar, MD14, Ann-Kathrin Eisfeld, MD15, Catherine Lai, MD, MPH16
AFFILIATIONS
1 University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
4 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
5 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
8 University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
11 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
12 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
13 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
14 University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
15 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
16 University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Introduction
Mixed phenotype acute leukemia (MPAL) is a rare, aggressive subtype of acute leukemia characterized by the co-expression of myeloid and lymphoid lineage markers with a median overall survival (OS) of 18 months. No treatment guidelines or prospective randomized trials exist, and current therapies are extrapolated from acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) paradigms, with evidence favoring ALL-directed regimens. However, most data derive from small, single academic center analyses using intensive chemotherapy, even though a large proportion of adult patients are older or harbor adverse-risk features such as TP53 mutations and comorbidities that may preclude intensive approaches. Venetoclax-hypomethylating agent combinations have transformed AML treatment for such patients, but whether these benefits extend to MPAL is unknown. We report the results from a multi-institutional consortium study comparing lower-intensity (LI) to standard induction chemotherapy (IC).
Methods
We retrospectively analyzed adult MPAL patients from 2 independent databases, the Myeloid Malignancy Association on Rapid Research Outcomes Group (MARROW) and the Flatiron database. Patients were classified into 3 treatment groups, ALL-IC, AML-IC, or LI. OS and disease-free survival (DFS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Complete remission (CR) and relapse rates were compared using Fisher’s exact test. Baseline characteristics between cohorts were compared to identify prognostic differences.
Results
A total of 145 patients (MARROW, n=52; Flatiron, n=93) were evaluated across 3 treatment groups (ALL-IC, n=45; AML-IC, n=49; LI, n=51). Treatment allocation differed markedly; ALL-IC in 50% of MARROW versus 20% of Flatiron patients (p=0.001), and allogeneic transplantation in 58% versus 32% (p=0.003), respectively. Flatiron patients were older (median 67 vs. 59 years; p=0.01), with a higher rate of abnormal karyotypes (100% vs. 71%; p<0.001) and higher TP53 mutation rates (35% vs. 0%; p=0.007).
In the pooled analysis, OS differed across groups (p<0.0001), with 2- and 5-year (yr) OS of 66% and 47% for ALL-IC; 65% and 45% for AML-IC, compared with 24% and 13% for LI. CR rates were significantly higher with IC [ALL-IC 80% (36/45), AML-IC 88% (43/49)] than with LI [41% (21/51); p<0.0001]. Among the 100 patients achieving CR, 33% (33/100) relapsed at comparable rates across groups (ALL-IC 36%, AML-IC 29%, LI 28%; p=0.84). DFS, evaluable in 99/100, did not differ significantly (p=0.078), with 2- and 5-yr DFS of 60% and 46% for ALL-IC; 55% and 47% for AML-IC; and 32% and 0% for LI. Bone marrow transplantation, performed in 41% (60/145), was associated with superior OS (unadjusted HR 0.22, 95% CI 0.14–0.37; p<0.001) and DFS (HR 0.37, 95% CI 0.21–0.63; p<0.001).
In cohort-specific analyses, Flatiron had inferior OS than MARROW. OS differed significantly by treatment group in both MARROW (p=0.0007) and Flatiron cohorts (p=0.003). In MARROW, the 2- and 5-yr OS rates were 67% and 57% for ALL-IC; 82% and 66% for AML-IC; and 32% and 0% for LI. In Flatiron, the 2- and 5-yr OS rates were 65% and 33% for ALL-IC; 58% and 36% for AML-IC; and 21% and 17% for LI. DFS reached significance only in MARROW (p=0.045) but not Flatiron (p=0.748). Among 40 evaluable MARROW patients, the 2- and 5-yr DFS were both 66% for ALL-IC; 83% for AML-IC; and 25% and 0% for LI. Among 59 evaluable Flatiron patients, the 2- and 5-yr DFS were 50% and 17% for ALL-IC; 44% and 34% for AML-IC; and 34% and 0% for LI.
Conclusion
IC, regardless of ALL or AML backbone, was associated with superior OS and CR compared with LI, although baseline differences and selection bias may have contributed to these findings. Notably, OS was lower in the community-predominant Flatiron cohort relative to the academic-predominant MARROW cohort, a disparity not observed in prior consortium analyses of other rare acute leukemia subtypes. However, Flatiron patients were older with a higher prevalence of adverse-risk genetic alterations, which may confound interpretation. These data provide benchmarks across the spectrum of treatment intensity in MPAL, including previously undercharacterized LI regimens. Prospective multicenter studies incorporating centralized diagnostic review are needed to evaluate optimal frontline treatment strategies and clarify the association between practice setting and outcomes in this rare, understudied leukemia.
DISCLOSURES
Yejin Andrea Kim, MD: No relevant conflicts of interest to declare.